Amplia Reports Improved Responses & Survival in ACCENT trial
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Amplia Therapeutics Ltd. reports significant findings from the ACCENT trial, highlighting four additional complete responses and improved overall survival data for patients with advanced pancreatic cancer. The company has been selected to present these findings at the upcoming American Association of Cancer Research annual meeting.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- Trading Halt
- Pause in Trading
- Amplia Therapeutics to Present at the Life Sciences Investor Forum on March 12th
- Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models
- Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial
Later from Amplia Therapeutics
- Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial
- Amplia Therapeutics Halts Recruitment in AMPLICITY Trial
- Accent Trial Mature Data Presented at International Conference
- Amplia and ANZGOG announce Ovarian Cancer Study
- Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics